Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.
Zastrozhin MS, Skryabin VY, Smirnov VV, Petukhov AE, Pankratenko EP, Zastrozhina AK, Grishina EA, Ryzhikova KA, Bure IV, Golovinskii PA, Koporov SG, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: skryabin vy. Gene. 2020 May 20;739:144513. doi: 10.1016/j.gene.2020.144513. Epub 2020 Feb 26. Gene. 2020. PMID: 32112986
Effects of CYP2C19*17 polymorphisms on the efficacy and safety of bromodigyrochlorophenylbenzodiazepine in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS, Antonenko AP, Nesterenko EV, Seyfullaeva LI, Mustafina VR, Esakova AP, Grishina EA, Sorokin AS, Skryabin VY, Savchenko LM, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: skryabin vy. Drug Metab Pers Ther. 2018 Dec 19;33(4):187-194. doi: 10.1515/dmpt-2018-0019. Drug Metab Pers Ther. 2018. PMID: 30325732
How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?
Skryabin VY, Zastrozhin MS, Torrado MV, Grishina EA, Ryzhikova KA, Shipitsyn VV, Galaktionova TE, Sorokin AS, Bryun EA, Sychev DA. Skryabin VY, et al. Drug Metab Pers Ther. 2020 Mar 5;35(1):/j/dmdi.2020.35.issue-1/dmpt-2019-0026/dmpt-2019-0026.xml. doi: 10.1515/dmpt-2019-0026. Drug Metab Pers Ther. 2020. PMID: 32134726
Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder.
Zastrozhin MS, Skryabin VY, Torrado M, Petrovna A, Sorokin AS, Grishina EA, Ryzhikova KA, Bedina IA, Buzik OZ, Chumakov EM, Savchenko LM, Brun EA, Sychev DA. Zastrozhin MS, et al. Among authors: skryabin vy. Pharmacogenomics. 2020 Jan;21(2):111-123. doi: 10.2217/pgs-2019-0019. Pharmacogenomics. 2020. PMID: 31957548
Pharmacogenetics of alcohol addiction: current perspectives.
Zastrozhin MS, Skryabin VY, Miroshkin SS, Bryun EA, Sychev DA. Zastrozhin MS, et al. Among authors: skryabin vy. Appl Clin Genet. 2019 Jul 11;12:131-140. doi: 10.2147/TACG.S206745. eCollection 2019. Appl Clin Genet. 2019. PMID: 31372024 Free PMC article.
Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA, Zastrozhin MS, Miroshnichenko II, Baymeeva NV, Smirnov VV, Grishina EA, Ryzhikova KA, Mirzaev KB, Markov DD, Skryabin VY, Snalina NE, Nosikova PG, Savchenko LM, Bryun EA. Sychev DA, et al. Among authors: skryabin vy. Drug Metab Pers Ther. 2017 Sep 26;32(3):129-136. doi: 10.1515/dmpt-2017-0021. Drug Metab Pers Ther. 2017. PMID: 28787271
77 results